Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

766
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
766
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

883
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
883
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

365
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
365
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

13.3K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
13.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

Orphanet journal of rare diseases·2022
Same author

Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.

Diabetes & metabolism·2021
Same author

Relationship between renal capacity to reabsorb glucose and renal status in patients with diabetes.

Diabetes & metabolism·2020
Same author

Whole-exome sequencing identifies the first French MODY 6 family with a new mutation in the NEUROD1 gene.

Diabetes & metabolism·2020
Same author

[Thyroiditis: What's new in 2019?]

La Revue de medecine interne·2020
Same author

Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).

Diabetes & metabolism·2019
Same journal

Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.

Diabetes & metabolism·2026
Same journal

Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors.

Diabetes & metabolism·2026
Same journal

Two faces of autoimmune hyperinsulinemia: contrasting type B insulin resistance syndrome and exogenous insulin antibody syndrome.

Diabetes & metabolism·2026
Same journal

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026
Same journal

Persistent burden and management gaps of hypoglycemia in pediatric type 1 diabetes: insights from the Epi-GLUREDIA Study.

Diabetes & metabolism·2026
Same journal

Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.

Diabetes & metabolism·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

3.0K

Potential risks associated with increased plasma plant-sterol levels.

B Vergès1, F Fumeron2

  • 1Inserm CRI 866, Department of Endocrinology-Diabetology, University Hospital, Dijon, France.

Diabetes & Metabolism
|December 16, 2014
PubMed
Summary
This summary is machine-generated.

Plant sterol intake lowers LDL cholesterol but may increase plasma plant sterol levels, raising concerns about cardiovascular risk. Further research is needed to clarify the association between plant sterols and cardiovascular events.

Keywords:
CardiovascularPlant sterolRisksSitosterolaemia

More Related Videos

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K
Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

4.6K

Related Experiment Videos

Last Updated: Apr 19, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

3.0K
Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K
Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

4.6K

Area of Science:

  • Nutritional Science
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Plant sterols reduce LDL cholesterol but elevate plasma plant sterol levels (sitosterol, campesterol).
  • Elevated plasma plant sterols are linked to sitosterolaemia and premature atherosclerosis.
  • The precise relationship between plasma plant sterol levels and cardiovascular disease (CVD) risk remains unclear.

Purpose of the Study:

  • To review the existing literature on the association between plasma plant sterol levels and cardiovascular disease.
  • To evaluate the potential cardiovascular risks associated with plant sterol consumption.

Main Methods:

  • Systematic review of observational studies and genome-wide association studies.
  • Analysis of conflicting results regarding plant sterol levels and cardiovascular risk.

Main Results:

  • Conflicting findings exist regarding the association between plasma plant sterol levels and CVD.
  • Large prospective trials suggest a potential increased cardiovascular risk with high plant sterol levels.
  • Some studies report no association or even an inverse relationship.

Conclusions:

  • Current data are inconclusive regarding the cardiovascular risk posed by plant sterols.
  • A potential cardiovascular risk cannot be definitively ruled out.
  • Prospective intervention trials are necessary to assess the impact of plant sterol-enriched foods on cardiovascular events.